{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:57:10Z","timestamp":1789390630221,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-55090-4","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:06:12Z","timestamp":1735862772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after \u2265 2 prior lines of chemotherapy: a phase Ib study"],"prefix":"10.1038","volume":"16","author":[{"given":"Ying","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8116-5293","authenticated-orcid":false,"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3911-748X","authenticated-orcid":false,"given":"Min","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaofeng","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinshuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanyuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-337X","authenticated-orcid":false,"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"55090_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/npjbcancer.2016.36","volume":"2","author":"F Pareja","year":"2016","unstructured":"Pareja, F. et al. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer 2, 16036 (2016).","journal-title":"NPJ Breast Cancer"},{"key":"55090_CR2","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1002\/cncr.23930","volume":"113","author":"NU Lin","year":"2008","unstructured":"Lin, N. U. et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113, 2638\u20132645 (2008).","journal-title":"Cancer"},{"key":"55090_CR3","doi-asserted-by":"publisher","first-page":"113422","DOI":"10.1016\/j.ejca.2023.113422","volume":"196","author":"A Galvin","year":"2024","unstructured":"Galvin, A. et al. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort. Eur. J. Cancer 196, 113422 (2024).","journal-title":"Eur. J. Cancer"},{"key":"55090_CR4","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","volume":"23","author":"M Kuksis","year":"2021","unstructured":"Kuksis, M. et al. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol. 23, 894\u2013904 (2021).","journal-title":"Neuro Oncol."},{"key":"55090_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","volume":"121","author":"A Darlix","year":"2019","unstructured":"Darlix, A. et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br. J. Cancer 121, 991\u20131000 (2019).","journal-title":"Br. J. Cancer"},{"key":"55090_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0665-1","volume":"18","author":"I Witzel","year":"2016","unstructured":"Witzel, I. et al. Breast cancer brain metastasis: biology and new clinical perspectives. Breast Cancer Res. 18, 8 (2016).","journal-title":"Breast Cancer Res."},{"key":"55090_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11095-017-2278-0","volume":"35","author":"AS Mohammad","year":"2018","unstructured":"Mohammad, A. S. et al. Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer. Pharm. Res. 35, 31 (2018).","journal-title":"Pharm. Res."},{"key":"55090_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11790-6","volume":"24","author":"W Huang","year":"2024","unstructured":"Huang, W. et al. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer. BMC Cancer 24, 39 (2024).","journal-title":"BMC Cancer"},{"key":"55090_CR9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2084","author":"P Schmid","year":"2023","unstructured":"Schmid, P. et al. First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2084 (2023).","journal-title":"Clin. Cancer Res."},{"key":"55090_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02677-x","author":"Z Jiang","year":"2024","unstructured":"Jiang, Z. et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-023-02677-x (2024).","journal-title":"Nat. Med."},{"key":"55090_CR11","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"JO Cortes","year":"2011","unstructured":"Cortes, J. O. et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet 377, 914\u2013923 (2011).","journal-title":"Lancet"},{"key":"55090_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","volume":"112","author":"P Yuan","year":"2019","unstructured":"Yuan, P. et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. Eur. J. Cancer 112, 57\u201365 (2019).","journal-title":"Eur. J. Cancer"},{"key":"55090_CR13","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 384, 1529\u20131541 (2021).","journal-title":"N. Engl. J. Med."},{"key":"55090_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer, E. P. et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 499\u2013511 (2021).","journal-title":"Lancet Oncol."},{"key":"55090_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.breast.2013.07.037","volume":"22","author":"G Curigliano","year":"2013","unstructured":"Curigliano, G. et al. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast 22, 650\u2013656 (2013).","journal-title":"Breast"},{"key":"55090_CR16","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/annonc\/mdw203","volume":"27","author":"X Pivot","year":"2016","unstructured":"Pivot, X. et al. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann. Oncol. 27, 1525\u20131531 (2016).","journal-title":"Ann. Oncol."},{"key":"55090_CR17","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.3390\/jcm11206021","volume":"11","author":"S Li","year":"2022","unstructured":"Li, S., Bao, C., Huang, L. & Wei, J. Current therapeutic strategies for metastatic triple-negative breast cancer: from pharmacists\u2019 perspective. J. Clin. Med. 11, 6021 (2022).","journal-title":"J. Clin. Med."},{"key":"55090_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s10549-020-05995-7","volume":"185","author":"JC Sachdev","year":"2021","unstructured":"Sachdev, J. C. et al. Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase. Breast Cancer Res Treat. 185, 759\u2013771 (2021).","journal-title":"Breast Cancer Res Treat."},{"key":"55090_CR19","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman, P. A. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 33, 594\u2013601 (2015).","journal-title":"J. Clin. Oncol."},{"key":"55090_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2218647","volume":"55","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases. Ann. Med. 55, 2218647 (2023).","journal-title":"Ann. Med."},{"key":"55090_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","volume":"108","author":"A Wang-Gillam","year":"2019","unstructured":"Wang-Gillam, A. et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur. J. Cancer 108, 78\u201387 (2019).","journal-title":"Eur. J. Cancer"},{"key":"55090_CR22","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/cpt.720","volume":"102","author":"BS Adiwijaya","year":"2017","unstructured":"Adiwijaya, B. S. et al. Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer. Clin. Pharm. Ther. 102, 997\u20131005 (2017).","journal-title":"Clin. Pharm. Ther."},{"key":"55090_CR23","first-page":"1178","volume":"13","author":"XY Ju","year":"2015","unstructured":"Ju, X. Y., Luo, X. M., Wang, Y. Q. & Ge, W. H. UGT1A1 genetic information combined with therapeutic drug monitoring in individualized treatment with irinotecan. Cent. South Pharm. 13, 1178\u20131182 (2015).","journal-title":"Cent. South Pharm."},{"key":"55090_CR24","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.7754\/Clin.Lab.2017.170105","volume":"63","author":"H Peng","year":"2017","unstructured":"Peng, H., Duan, Z., Pan, D., Wen, J. & Wei, X. UGT1A1 gene polymorphism predicts irinotecan-induced severe neutropenia and diarrhea in Chinese cancer patients. Clin. Lab. 63, 1339\u20131346 (2017).","journal-title":"Clin. Lab."},{"key":"55090_CR25","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J. Clin. Oncol. 38, 1346\u20131366 (2020).","journal-title":"J. Clin. Oncol."},{"key":"55090_CR26","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J. Clin. Oncol. 36, 2105\u20132122 (2018).","journal-title":"J. Clin. Oncol."},{"key":"55090_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1200\/JCO.2016.34.15_suppl.1037","volume":"34","author":"NJ Robert","year":"2016","unstructured":"Robert, N. J. et al. Predictive value of topoisomerase 1 by immunohistochemistry (TOP1 IHC) in patients with metastatic breast cancer receiving irinotecan-based therapy. J. Clin. Oncol. 34, 1037 (2016).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55090-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55090-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55090-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:06:45Z","timestamp":1735866405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55090-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55090"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-55090-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"18 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.L., M.N. and X.Z. are employees of CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. B.X. receives consulting fees from AstraZeneca and Novartis. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}